| 摘要 |
The purpose of the present invention is to provide a novel mesothelioma treatment method having a high degree of safety. CD26 is overexpressed in mesotheliomas and is considered to be very safe. Investigation by the inventors revealed that combining the anti-CD26 antibody and the standard cisplatin-pemetrexed combination therapy enhances the antiproliferative effect on mesotheliomas. In addition, the inventors found that as a result of investigating the effect of the combined use of a humanized anti-CD26 antibody and gemcitabine on the proliferation of mesothelioma cell lines, it is possible to provide a mesothelioma treatment method that is highly effective and extremely safe by combining the anti-CD26 antibody and gemcitabine. Furthermore, as a result of coupling the anti-CD26 antibody (YS110) and triptolide using a divalent crosslinking agent in combination therapy using the anti-CD26 antibody, the inventors succeeded in obtaining a novel antibody-drug conjugate (Y-TR1) that is extremely effective against CD26-positive malignant mesothelioma cells. |
